MTOR and neoplasm: Nitazoxanide, a thiazolide, exerts anti-tumor effects by activating AMPK while inhibiting AKT/mTOR and Wnt/β-catenin signaling, thereby reducing proliferation and stemness—effects that are further enhanced when combined with farnesoid X receptor (FXR) agonists [72].